MRUS · Insider Trading
Merus N.V. Common Shares
Every open-market purchase and sale reported by MRUS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-30 | A/s Genmab | 10%+ Owner | Buy | −74,811,415 | −$7.26B |
| 2025-12-29 | A/s Genmab | 10%+ Owner | Buy | +815,444 | +$79.10M |
| 2025-12-22 | A/s Genmab | 10%+ Owner | Buy | +278,441 | +$27.01M |
| 2025-12-18 | A/s Genmab | 10%+ Owner | Buy | +271,547 | +$26.34M |
| 2025-12-12 | Victor Sandor | Director | D | −84,806 deriv. | — |
| 2025-12-12 | Maxine Gowen | Director | D | −73,252 deriv. | — |
| 2025-12-12 | Sven Ante Lundberg | President, CEO & PEO | U | −83,435 | −$8.09M |
| 2025-12-12 | Jason Haddock | Director | D | −30,881 deriv. | — |
| 2025-12-12 | Fabian Zohren | Chief Medical Officer | D | −233,943 deriv. | — |
| 2025-12-12 | Len Kanavy | Director | D | −98,124 deriv. | — |
| 2025-12-12 | Harry Shuman | VP Controller, PAO | U | −11,002 | −$1.07M |
| 2025-12-12 | Mark T Iwicki | Director | U | −73,576 | −$7.14M |
| 2025-12-12 | Peter B. Silverman | COO & GC | D | −505,914 deriv. | — |
| 2025-12-12 | Anand Mehra | Director | D | −103,939 deriv. | — |
| 2025-12-12 | Paolo Pucci | Director | D | −76,437 deriv. | — |
| 2025-12-12 | Gregory D Perry | Chief Financial Officer & PFO | D | −662,126 deriv. | — |
| 2025-12-10 | Harry Shuman | VP Controller, PAO | MIXED | — | −$126.50K |
| 2025-11-28 | Sven Ante Lundberg | President, CEO & PEO | G | −115,305 | — |
| 2025-11-28 | Harry Shuman | VP Controller, PAO | MIXED | — | −$796.14K |
| 2025-07-18 | Peter B. Silverman | COO & GC | MIXED | — | −$889.25K |
| 2025-07-11 | Peter B. Silverman | COO & GC | MIXED | — | −$855.16K |
| 2025-06-24 | Peter B. Silverman | COO & GC | MIXED | — | −$1.16M |
| 2025-05-27 | Mark T Iwicki | Director | A | +13,193 deriv. | — |
| 2025-05-27 | Len Kanavy | Director | A | +13,193 deriv. | — |
| 2025-05-27 | Victor Sandor | Director | A | +13,193 deriv. | — |
| 2025-05-27 | Jason Haddock | Director | A | +13,193 deriv. | — |
| 2025-05-27 | Paolo Pucci | Director | A | +13,193 deriv. | — |
| 2025-05-27 | Anand Mehra | Director | A | +13,193 deriv. | — |
| 2025-05-27 | Maxine Gowen | Director | A | +13,193 deriv. | — |
| 2025-04-21 | Sven Ante Lundberg | President, CEO & PEO | M | +30,297 | +$405.89K |
| 2025-03-25 | Harry Shuman | VP Controller, PAO | M | +5,000 | — |
| 2025-03-25 | Harry Shuman | VP Controller, PAO | MIXED | −1,000 | −$193.99K |
| 2025-02-21 | Sven Ante Lundberg | President, CEO & PEO | G | — | — |
| 2025-02-18 | Sven Ante Lundberg | President, CEO & PEO | M | +16,372 | +$399.97K |
| 2025-01-31 | Peter B. Silverman | COO & GC | A | +125,000 deriv. | — |
| 2025-01-31 | Sven Ante Lundberg | President, CEO & PEO | A | +300,000 deriv. | — |
| 2025-01-31 | Fabian Zohren | Chief Medical Officer | A | +50,000 deriv. | — |
| 2025-01-31 | Gregory D Perry | Chief Financial Officer & PFO | A | +100,000 deriv. | — |
| 2025-01-31 | Harry Shuman | VP Controller, PAO | A | +23,420 deriv. | — |
| 2024-08-22 | Harry Shuman | VP Controller, PAO | MIXED | — | −$270.00K |
| 2024-07-03 | Fabian Zohren | Chief Medical Officer | A | +183,943 deriv. | — |
| 2024-06-28 | Peter B. Silverman | COO & GC | MIXED | — | −$420.60K |
| 2024-06-20 | Peter B. Silverman | COO & GC | MIXED | — | −$1.99M |
| 2024-06-12 | Harry Shuman | VP Controller, PAO | MIXED | — | −$475.46K |
| 2024-06-06 | Harry Shuman | VP Controller, PAO | MIXED | — | −$317.35K |
| 2024-05-09 | Sven Ante Lundberg | President, CEO & PEO | A | +360,000 deriv. | — |
| 2024-05-09 | Paolo Pucci | Director | A | +8,844 deriv. | — |
| 2024-05-09 | Victor Sandor | Director | A | +8,844 deriv. | — |
| 2024-05-09 | Andrew Joe | SVP, CMO | A | +107,300 deriv. | — |
| 2024-05-09 | Len Kanavy | Director | A | +8,844 deriv. | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MRUS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.